Evaluation of Neonatal Screening for Congenital Adrenal Hyperplasia
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Neonatal screening for congenital hypothyroidism has been effective in early detection and treatment of the condition. The position with respect to neonatal screening for congenital adrenal hyperplasia has been debated for many years. Some countries have performed congenital adrenal hyperplasia screening for many years, others have conducted pilot studies that were then not adopted. This article endeavours to summarize the complex issues behind decisions whether to screen or not and summarizes the findings of neonatal congenital adrenal hyperplasia screening programmes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genotyping steroid 21-hydroxylase deficiency: hormonal reference data
NEW, M. I., LORENZEN, F., LERNER, A. J., KOHN, B., OBERFIELD, S. E., POLLACK, M. S., DUPONT, B., STONER, E., LEVY, D. J., PANG, S., et al. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-2-320 · Cited by 624 · cited 1×
“The Swedish and French experience with molecular biology is that the additional cost of confirmatory tests to the screening programme does not make a great deal of impact on the cost per case detected. There are other benefits to the family, genetic counsellor, and the genetics laboratory in having information about t…”
BackgroundSpeiser, P. W., Dupont, J., Zhu, D., Serrat, J., Buegeleisen, M., Tusie-Luna, M. T., Lesser, M., New, M. I., & White, P. C. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115897 · Cited by 572 · cited 1×
“There is evidence that the type of mutation in the CYP21 gene and, consequently, the degree of enzyme deficiency are what primarily affect the severity of the disease. Salt-wasting CAH is most likely to be caused by mutations that result in 0–1p of normal enzyme activity; simple virilizing CAH is associated with mutat…”
BackgroundPang, S., Wallace, M. A., Hofman, L., Thuline, H. C., Dorche, C., Lyon, I. C. T., Dobbins, R. H., Kling, S., Fujieda, K., & Suwa, S. (1988) · Journal of Urology · doi:10.1016/s0022-5347(17)42164-1 · Cited by 392
Wedell, A. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.5.1145 · Cited by 370
Therrell, B. L., Berenbaum, S. A., Manter-Kapanke, V., Simmank, J., Korman, K., Prentice, L., Gonzalez, J., & Gunn, S. (1998) · Pediatrics · doi:10.1542/peds.101.4.583 · Cited by 344
PANG, S., HOTCHKISS, J., DRASH, A. L., LEVINE, L. S., & NEW, M. I. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-45-5-1003 · Cited by 293
Newborn screening for congenital adrenal hyperplasia
Therrell, B. L. (2001) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(08)70017-3 · Cited by 221
Wong, T., Shackleton, C. H., Covey, T. R., & Ellis, G. (1992) · Clinical Chemistry · doi:10.1093/clinchem/38.9.1830 · Cited by 159
Allen, D. B., Hoffman, G. L., Fitzpatrick, P., Laessig, R., Maby, S., & Slyper, A. (1997) · The Journal of Pediatrics · doi:10.1016/s0022-3476(97)70321-4 · Cited by 153
Thilén, A., Nordenström, A., Hagenfeldt, L., von Döbeln, U., Guthenberg, C., & Larsson, A. (1998) · PEDIATRICS · doi:10.1542/peds.101.4.e11 · Cited by 151
Nordenström, A., Thilén, A., Hagenfeldt, L., Larsson, A., & Wedell, A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.5.5651 · Cited by 108
Effect of newborn screening for congenital adrenal hyperplasia
Brosnan, P. G., Brosnan, C. A., Kemp, S. F., Domek, D. B., Jelley, D. H., Blackett, P. R., & Riley, W. J. (1999) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.153.12.1272 · Cited by 91
Mortality in patients with congenital adrenal hyperplasia: a cohort study
Swerdlow, A. J., Higgins, C. D., Brook, C. G. D., Dunger, D. B., Hindmarsh, P. C., Price, D. A., & Savage, M. O. (1998) · The Journal of Pediatrics · doi:10.1016/s0022-3476(98)70060-5 · Cited by 77
Presentation, acute illness, and learning difficulties in salt wasting 21-hydroxylase deficiency
Donaldson, M. D., Thomas, P. H., Love, J. G., Murray, G. D., McNinch, A. W., & Savage, D. C. (1994) · Archives of Disease in Childhood · doi:10.1136/adc.70.3.214 · Cited by 60
Saedi, S. A., Dean, H., Dent, W., Stockl, E., & Cronin, C. (1996) · PEDIATRICS · doi:10.1542/peds.97.1.100 · Cited by 55
Cited by
(2002) · Hormone Research in Paediatrics · doi:10.1159/000065490 · Cited by 458
How Many Deaths Can Be Prevented by Newborn Screening for Congenital Adrenal Hyperplasia?
Grosse, S. D., & Van Vliet, G. (2007) · Hormone Research in Paediatrics · doi:10.1159/000098400 · Cited by 102
“Since then, newborn screening for CAH has become adopted in most parts of the United States and in a number of other countries, including New Zealand, Japan, Israel, Sweden, Switzerland, France, Austria, and the Netherlands [”
BackgroundSchwarz, E., Liu, A., Randall, H., Haslip, C., Keune, F., Murray, M., Longo, N., & Pasquali, M. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e3181aa3777 · Cited by 97
“Impaired activity of this enzyme results in increased 17-OHP, defective synthesis of cortisol and mineralcorticoids, increased synthesis of androstenedione, and decreased central feedback (increased production of adrenocorticotropic hormone) resulting in adrenal hyperplasia, virilization, and salt-wasting crisis, whic…”
BackgroundManagement of Congenital Adrenal Hyperplasia: Results of the ESPE Questionnaire
Riepe, F. G., Krone, N., Viemann, M., Partsch, C.-J., & Sippell, W. G. (2002) · Hormone Research in Paediatrics · doi:10.1159/000065492 · Cited by 72
Nordenström, A., Ahmed, S., Jones, J., Coleman, M., Price, D. A., Clayton, P. E., & Hall, C. M. (2005) · Hormone Research in Paediatrics · doi:10.1159/000082896 · Cited by 66
Metadata
- Authors
- Honour, J. W., & Torresani, T.
- Venue
- Hormone Research in Paediatrics
- Publisher
- S. Karger AG
- Published
- 2001
- Volume
- 55
- Issue
- 4
- Pages
- 206-211
- ISSN
- 1663-2818 (ISSN-L)
- 1663-2826
- OpenAlex
- W1994645492
- Cited by
- 57
- References
- 15
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.